Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.

Keith, Michael S; Wilson, Rosamund J; Preston, Peter; Copley, J Brian

Keith, Michael S; Wilson, Rosamund J; Preston, Peter; Copley, J Brian.

Affiliation

Keith MS; Shire, Wayne, Pennsylvania, USA. Electronic address: mkeith@shire.com.
Wilson RJ; Spica Consultants, Marlborough, Wiltshire, United Kingdom.
Preston P; Shire, Wayne, Pennsylvania, USA.
Copley JB; Shire, Wayne, Pennsylvania, USA.

Clin Ther ; 36(9): 1276-86, 2014 Sep 01.

Article in En | MEDLINE | ID: mdl-25069799

Subject(s)

Chelating Agents/economics; Kidney Failure, Chronic/economics; Lanthanum/economics; Sevelamer/economics; Adult; Aged; Chelating Agents/therapeutic use; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia/drug therapy; Kidney Failure, Chronic/therapy; Lanthanum/therapeutic use; Male; Middle Aged; Renal Dialysis/economics; Sevelamer/therapeutic use; United States

Key words

cost-minimization; daily dose; end-stage renal disease; hyperphosphatemia; lanthanum carbonate; phosphate binder; sevelamer hydrochloride

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chelating Agents / Sevelamer / Kidney Failure, Chronic / Lanthanum Type of study: Clinical_trials / Health_economic_evaluation Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Clin Ther Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google